UEG WEEK 2024

The battle of IL-23s

The new kids on the block

TL1A - a hot new target?

S1P modulators - dead or alive?

Did we get the pharmacogentics of drugs right?

A focus on bowel urgency

P19 antagonists - on the way to disease clearence!?

What is early disease? Getting the right drug to the right patient

Hot topic deescalation - patients' wish & scientific evidence

S1P modulators - efficacy, safety and the future evolution

RW data of Ustekinumab and the role of biosimilars

JAKies side effects - what is the current place for JAKies?

How to treat extraintestinal manifestations?

Fatigue - still a black box?

Prime time for ultrasound use

Impact of Guselkumab maintenance on histological and endoscopic outcomes in UC

Tamuzimod for long term extension

Long term persistence of Ustekinumab in moderate to severe Crohn’s disease

Guselkumab in UC - QUASAR maintenance data

Tofacitinib is effective in UC associated spondyloarthropathy

Mirikizumab is able to induce disease clearance in UC

anti-TL1A in UC

Παρατεταμένη ανταπόκριση στο ustekinumab ασθενών με μέτρια προς βαρειά νόσο του Crohn

anti-TL1A nella CU

Tamuzimod per estensione a lungo termine

Guselkumab bei Colitis ulcerosa - die QUASAR Maitenance-Daten

Real world data on Risankizumab effectiveness in CD

Effects of Mirikizumab & Ustekinumab on histological inflammation in CD

Guselkumab in patients with Crohn´s disease

Risankizumab in CD – expectations vs. reality

Risankizumab efficacy in CD

Guselkumab nei pazienti con malattia di Crohn

Efficacité du risankizumab dans la maladie de Crohn

Dati real-world di efficacia di Risankizumab in malattia di Crohn

Ryzankizumab w chorobie Crohna – oczekiwania vs. Rzeczywistość

Dose adjustment for subcutaneous Infliximab

How to diagnose PSC associated to IBD

Evidence based surgery for IBD?

How to diagnose PSC associated to IBD

כירורגיה מבוססת ראיות במחלות מעי דלקתיות?

Dosisanpassung bei subkutanem Infliximab

Comment diagnostiquer la CSP associée aux MiCi?

Comment diagnostiquer la CSP associée aux MiCi ?

Extended induction response in week 12 in non-responder patients with Mirikizumab

What treatment after Vedolizumab in UC?

Long-term extension of Mirikizumab - barely any steroids needed!

Extended induction treatment in active UC can capture non responders to Mirikizumab

Long-term extension of Mirikizumab - significant added benefit!

Live biotherapeutic product for acute pouchitis

Long-term Extension von Mirikizumab - kaum noch Steroide notwendig!

Levend biotherapeutisch medicijn voor acute pouchitis

Παράταση της θεραπείας εφόδου αυξάνει την ανταπόκριση στο miricizumab ασθενών με ενεργό ελκώδη κολίτιδα

Long-term Extension von Mirikizumab - deutlicher Zusatznutzen!

Quel traitement après le Vedolizumab dans la RCH?

Induzione prolungata con Mirikizumab in pazienti che non raggiungono una risposta clinica a 12 settimane

Vedolizumab is more effective in early Crohn´s disease

Early disease loves Vedolizumab

Vedolizumab in early CD

Data on interaction between biologics and post-operative recurrence

Early treatment with Vedolizumab in patients with CD

Ileocecal resection in CD – GI functional consequences

Efficacité du vedolizumab dans les formes précoces

Zaburzenia czynności przewodu pokarmowego po resekcji ileocekalnej w chorobie Crohna

Früher Einsatz von Vedolizumab bei Patienten mit Morbus Crohn

Interactions entre le traitements biologiques et la chirurgie

De efficaciteit van vedolizumab is beter bij vroege ziekte van Crohn

Tulisokibart - a new therapeutic option in UC

Divine support for intestinal fibrosis in UC & CD

Cellular therapies in IBD – Old and New

Topical JAKies - let's try again!

RXC008 - novel mechanism of action for fibrostenosing Crohn´s disease

Tulisokibart - new anti-TL1A agent for treating CD

Dezidierte Unterstützung bei intestinaler Fibrose bei UC & CD

Tulisokibart - un nuovo anti-TL1A per il trattamento della malattia di Crohn

RXC008 - un nuovo meccanismo d’azione per la malattia di Crohn fibrostenosante

Topische JAKies - auf ein Neues!

Tulisokibart - eine neue Therapieoption bei CU

טיפולים תאיים במחלות מעי דלקתיות-ישן וחדש

Colorectal cancer risk and biologicals in IBD patients

Mirikizumab improves fatigue in patients with CD

Thiopurines and risk of cancer in IBD

Long term safety of ozanimod in UC

Risico op colorectaal carcinoom bij IBD patienten onder biologische therapieen

Tiopuryny a ryzyko onkologiczne w IBD